Irlanti - englanti - HPRA (Health Products Regulatory Authority)

pfizer healthcare ireland - tobramycin - solution for injection - 40 milligram(s)/millilitre - other aminoglycosides; tobramycin

Yhdysvallat - englanti - NLM (National Library of Medicine)

pfizer laboratories div pfizer inc - tobramycin sulfate (unii: hjt0rxd7jk) (tobramycin - unii:vz8rrz51vk) - tobramycin 40 mg in 1 ml

Yhdysvallat - englanti - NLM (National Library of Medicine)

fresenius kabi usa, llc - tobramycin sulfate (unii: hjt0rxd7jk) (tobramycin - unii:vz8rrz51vk) - tobramycin 40 mg in 1 ml

Yhdysvallat - englanti - NLM (National Library of Medicine)

preferred pharmaceuticals inc. - tobramycin (unii: vz8rrz51vk) (tobramycin - unii:vz8rrz51vk) - tobramycin 3 mg in 1 ml

Australia - englanti - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - tobramycin, quantity: 80 mg - injection, solution - excipient ingredients: sodium hydroxide; sodium metabisulfite; phenol; water for injections; sulfuric acid; disodium edetate - for the treatment of serious infections of the following type where they are caused by susceptible organisms: skin and skin structure infections including burns, bone infections; gastrointestinal infections including peritonitis; central nervous system infections including meningitis, septicaemia and neonatal sepsis; lower respiratory tract infections including pneumonia, bronchopneumonia, and acute bronchitis; complicated and recurrent urinary tract infections such as pyelonephritis and cystitis.,aminoglycosides, including tobramycin, should not be used in uncomplicated initial episodes of urinary tract infection unless the causative organisms are not susceptible to other less toxic antibiotics.,tobramycin can be used in serious staphylococcal infections for which penicillin or other less toxic drugs are contraindicated and where susceptibility testing and clinical judgement indicate its use. if susceptibility tests show a resistance to tobramycin in the causative organisms other appropriate therapy should be instituted.,note that bacterial cultures should bo obtained before and during treatment to isolate and identify etiologic organisms and to test their susceptibility to tobramycin. if the organisms are resistant, other appropriate therapy should be instituted. in patients in whom gram-negative septicaemia, neonatal sepsis or meningitis is suspected, including those in whom concurrent therapy with a penicillin or cefalosporin and an aminoglycoside may be indicated, tobramycin therapy may be initiated before results of susceptibility studies are obtained. the decision to continue tobramycin therapy should be based upon the results of susceptibility studies, the severity of infection and the important additional concepts discussed in the product information leaflet.

Yhdysvallat - englanti - NLM (National Library of Medicine)

preferred pharmaceuticals, inc - tobramycin (unii: vz8rrz51vk) (tobramycin - unii:vz8rrz51vk) - tobramycin 3 mg in 1 ml

Australia - englanti - Department of Health (Therapeutic Goods Administration)

luminarie pty ltd - tobramycin, quantity: 60 mg/ml - inhalation, conventional - excipient ingredients: sodium hydroxide; sulfuric acid; water for injections; sodium chloride - tobramycin wkt solution is indicated for the management of cystic fibrosis patients with p. aeruginosa infections.,safety and efficacy have not been demonstrated in patients under the age of 6 years, patients with fev1 less than or equal to 25 percent or more than or equal to 80 percent predicted at screening, or patients colonized with burkholderia cepacia (see clinical trials).

Yhdysvallat - englanti - NLM (National Library of Medicine)

rebel distributors corp - tobramycin (unii: vz8rrz51vk) (tobramycin - unii:vz8rrz51vk) - tobramycin ophthalmic solution is a topical antibiotic indicated in the treatment of external infections of the eye and its adnexa caused by susceptible bacteria. appropriate monitoring of bacterial response to topical antibiotic therapy should accompany the use of tobramycin ophthalmic solution. clinical studies have shown tobramycin to be safe and effective for use in children. tobramycin ophthalmic solution is contraindicated in patients with known hypersensitivity to any of its components.

Yhdysvallat - englanti - NLM (National Library of Medicine)

stat rx usa llc - tobramycin (unii: vz8rrz51vk) (tobramycin - unii:vz8rrz51vk) - tobramycin ophthalmic solution usp, 0.3% is a topical antibiotic indicated in the treatment of external infections of the eye and its adnexa caused by susceptible bacteria. appropriate monitoring of bacterial response to topical antibiotic therapy should accompany the use of tobramycin ophthalmic solution usp, 0.3%. clinical studies have shown tobramycin to be safe and effective for use in pediatric patients. tobramycin ophthalmic solution usp, 0.3% is contraindicated in patients with known hypersensitivity to any of its components.

Yhdysvallat - englanti - NLM (National Library of Medicine)

direct rx - tobramycin (unii: vz8rrz51vk) (tobramycin - unii:vz8rrz51vk) - tobramycin ophthalmic solution is a topical antibiotic indicated in the treatment of external infections of the eye and its adnexa caused by susceptible bacteria. appropriate monitoring of bacterial response to topical antibiotic therapy should accompany the use of tobramycin ophthalmic solution. clinical studies have shown tobramycin to be safe and effective for use in children. close tobramycin ophthalmic solution is contraindicated in patients with known hypersensitivity to any of its components. close